Giorgia Sulis1, Silvia Amadasi1, Anna Odone2, Martina Penazzato3, Alberto Matteelli1. 1. From the University Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV co-infection and for TB elimination, University of Brescia, Brescia, Italy. 2. Unit of Public Health, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy. 3. HIV/AIDS Department, World Health Organization, Geneva, Switzerland.
Abstract
BACKGROUND: Tuberculosis (TB) is the major cause of mortality in HIV-infected children globally. Current guidelines about the management of antiretroviral therapy in children with TB are based on a limited number of nonrandomized studies involving small numbers of participants. The aim of the study was to systematically retrieve and critically appraise available evidence on the efficacy and safety of different antiretroviral regimens in children with HIV infection who are receiving treatment for active TB. METHODS: We conducted a systematic review of the literature according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Records were retrieved through March 2016 from Medline, Embase and manual screening of key conference proceedings. Four specific research questions assessing available treatment options were defined. RESULTS: Although 4 independent searches were conducted (1 for each Population, Intervention, Comparator, Outcomes question), results were elaborated and interpreted together because of significant overlap among the retrieved records. Six observational studies were selected for qualitative synthesis while meta-analysis could not be performed. CONCLUSION: Evidence for optimal treatment options for HIV/TB coinfected children is limited. As the global community strives to reach the fast-track HIV treatment targets and eliminate childhood TB deaths, it must ensure that coinfected children are included in key treatment studies and expand this neglected but crucial area of research.
BACKGROUND:Tuberculosis (TB) is the major cause of mortality in HIV-infectedchildren globally. Current guidelines about the management of antiretroviral therapy in children with TB are based on a limited number of nonrandomized studies involving small numbers of participants. The aim of the study was to systematically retrieve and critically appraise available evidence on the efficacy and safety of different antiretroviral regimens in children with HIV infection who are receiving treatment for active TB. METHODS: We conducted a systematic review of the literature according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Records were retrieved through March 2016 from Medline, Embase and manual screening of key conference proceedings. Four specific research questions assessing available treatment options were defined. RESULTS: Although 4 independent searches were conducted (1 for each Population, Intervention, Comparator, Outcomes question), results were elaborated and interpreted together because of significant overlap among the retrieved records. Six observational studies were selected for qualitative synthesis while meta-analysis could not be performed. CONCLUSION: Evidence for optimal treatment options for HIV/TB coinfected children is limited. As the global community strives to reach the fast-track HIV treatment targets and eliminate childhood TB deaths, it must ensure that coinfected children are included in key treatment studies and expand this neglected but crucial area of research.
Authors: Anthony Enimil; Sampson Antwi; Hongmei Yang; Albert Dompreh; Wael A Alghamdi; Fizza S Gillani; Antoinette Orstin; Dennis Bosomtwe; Theresa Opoku; Jennifer Norman; Lubbe Wiesner; Taimour Langaee; Charles A Peloquin; Michael H Court; David J Greenblatt; Awewura Kwara Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Mutsa Bwakura Dangarembizi; Pearl Samson; Edmund V Capparelli; Carolyn Bolton Moore; Patrick Jean-Philippe; Stephen A Spector; Nahida Chakhtoura; Alex Benns; Bonnie Zimmer; Lynette Purdue; Chivon Jackson; Carole Wallis; Jennifer L Libous; Ellen G Chadwick Journal: J Acquir Immune Defic Syndr Date: 2019-08-01 Impact factor: 3.731